Brief: Idera Pharmaceuticals Announces Final Clinical Safety And Efficacy Data From Illuminate-204 Trial In Advanced Melanoma

Aceragen

21/04/2020 12:37

April 21 (Reuters) - Idera Pharmaceuticals Inc  IDRA.O :
    * IDERA PHARMACEUTICALS ANNOUNCES FINAL CLINICAL SAFETY AND
EFFICACY DATA FROM ILLUMINATE-204 TRIAL IN ADVANCED MELANOMA
    * IDERA PHARMACEUTICALS INC - ILLUMINATE-204 TRIAL IN
ADVANCED
MELANOMA SHOWED OVERALL RESPONSE RATE OF 22%
    * IDERA PHARMACEUTICALS INC - ILLUMINATE-204 TRIAL IN
ADVANCED
MELANOMA SHOWED DISEASE CONTROL RATE OF 71%
    * IDERA PHARMACEUTICALS INC - ILLUMINATE-204 TRIAL IN
ADVANCED
MELANOMA SHOWED MEDIAN OVERALL SURVIVAL OF 21 MONTHS
    * IDERA PHARMACEUTICALS INC - KEY TOPLINE DATA FROM
ILLUMINATE-301
EXPECTED IN Q1 2021

Source text for Eikon:  ID:nGNX6gc3WB 
Further company coverage:  IDRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))